NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)– NeOnc Technologies Holdings (NASDAQ: NTHI) is becoming a prominent player, as brain cancer research is entering an increasingly sophisticated era.
However, one of the field’s biggest problems remains stubbornly simple: getting effective therapy to the tumor while protecting the brain from additional damage. A July 2026 review in Science Translational Medicine described glioblastoma as remaining one of the most aggressive adult brain cancers, with survival still largely unchanged despite advances in molecular diagnostics and supportive care. At the same time, researchers are pursuing an expanding menu of approaches; targeted therapies, immunotherapy, tumor-treating fields, focused delivery technologies and molecularly selected treatments.
One of the most important developments has been the increasing use of molecular biomarkers to divide brain tumors into more precisely defined diseases. The FDA's recent brain-tumor approvals illustrate the trend: therapies are increasingly being developed around specific molecular alterations rather than treating every tumor as biologically identical. Vorasidenib, for example, targets susceptible IDH1/IDH2-mutant tumors, while other recent approvals have focused on specific alterations in pediatric brain cancers.
That is where NeOnc enters the story with NEO100. Rather than attempting to solve the blood-brain barrier problem by forcing a conventional systemic drug through it, NEO100 uses an intranasal delivery approach designed to reach the central nervous system through the nasal/olfactory pathway. The company's Phase 2a study specifically enrolled patients with recurrent or progressive Grade III and Grade IV glioma carrying an IDH1 mutation; a biomarker-defined population where the company is attempting to establish a targeted development path.
The August 2026 Phase 2a readout gives investors and researchers a reason to pay attention, while also demanding caution. NeOnc reported six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and five of 24 patients remained on treatment at the data cutoff. The company also reported no major toxicities across the cohort, with adverse events predominantly low-grade.
The appropriate takeaway being that NEO100 generated a clinical signal worthy of further investigation.
The broader competitive landscape underscores both the opportunity and the challenge. The National Cancer Institute currently lists numerous active glioblastoma trials involving combinations of chemotherapy, radiation, immunotherapy, targeted agents, tumor-treating fields and other experimental approaches. Meanwhile, Novocure's Phase 3 TRIDENT study did not meet its primary endpoint for overall survival when tumor-treating fields were initiated earlier, illustrating how difficult it remains to translate promising therapeutic concepts into statistically conclusive clinical benefits.
For NeOnc, the next major question is therefore whether the NEO100 signal can be reproduced in a larger, better-controlled study. The company says it plans to seek a Type B meeting with the FDA to discuss a potential registrational pathway for recurrent IDH1-mutant high-grade glioma. That regulatory discussion could help clarify what evidence would be required for the program's next stage.
The bigger significance of NEO100 may ultimately extend beyond a single drug. If intranasal delivery can demonstrate that therapeutically meaningful exposure to the brain can be achieved while maintaining tolerability, it could strengthen interest in the nose-to-brain delivery concept itself.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
